<DOC>
	<DOCNO>NCT00113984</DOCNO>
	<brief_summary>This study evaluate side effect fix dose vaccine GM-CSF increase dos anti-CTLA-4 antibody patient advanced prostate cancer . The vaccine consist `` prim vaccine '' call PROSTVAC/TRICOM , make vaccinia virus , `` boost vaccine '' call PROSTVAC-F/TRICOM , make fowlpox virus . GM-CSF chemical boost immune system , anti-CTLA-4 antibody protein may improve anti-tumor activity response vaccine . DNA insert prim boost vaccine virus cause production protein enhance immune activity also produce prostate specific antigen ( PSA ) -a protein normally produce patient 's tumor cell . Patients 18 year age old androgen-insensitive prostate cancer spread beyond original site may eligible 7-month study . Candidates must disease worsen despite treatment hormones one chemotherapy regimen . Their tumor must produce PSA , must history allergy egg egg product Candidates screen medical history physical examination , blood urine test , electrocardiogram , pathological confirmation diagnosis presence PSA marker , chest x-ray , image study assess extent tumor , , clinically indicate , cardiologic evaluation . Participants receive prim vaccination study day 1 . After 2 week every 4 week study , receive boost vaccine . All vaccine inject skin . On day vaccination daily next 3 day , patient receive injection GM-CSF increase number immune cell vaccination site . On day first six boost vaccination , receive anti-CTLA-4 antibody infusion vein 90 minute . Patients monitor safety treatment response follow test procedure : - Blood urine test monthly , often need , monitor liver , kidney , organ function . - Imaging study assess tumor start treatment , around study day 99 183 , every 3 month study . - Apheresis ( procedure collect immune cell call lymphocyte ) measure immune response treatment . Apheresis do three time : start study around study day 99 183 . For procedure , blood collect needle arm vein . The blood circulates machine separate component spin , lymphocytes extract . The rest blood return patient needle . This do participant tissue marker HLA-A2 ( 50 % patient ) . Patients whose disease respond treatment develop severe side effect may continue treatment beyond initial 7-month study period vaccine alone ( without antibody ) . After treatment complete , patient monitor 15 year . This include medical history physical examination 5 year follow last vaccination . Information beyond 5 year collect year telephone .</brief_summary>
	<brief_title>Vaccine Antibody Treatment Prostate Cancer</brief_title>
	<detailed_description>Background : - Adenocarcinoma prostate common cancer diagnosis American male , second lead cause cancer death . - The propose vaccine strategy represent third-generation design elicit T-cell immune response cell express PSA show break tolerance self-antigen , cause objective response PSA decline patient metastatic AIPC . - This strategy also utilize antibody CTLA-4 may block normal signal regulate immune response follow active vaccination . - Anti CTLA-4 antibody associate autoimmune event generally manageable associate clinical response . Objectives : - To determine safety tolerability combination fix dose vaccine anti-CTLA4 , dose escalate . - To evaluate immunologic response ( measured increase PSA specific T-cells measure ELISPOT HLA-A2+ patient ) , clinical response ( measure RECIST PSA consensus criterion ) . Eligibility : - Must metastatic androgen insensitive prostate cancer bone pain require narcotic prior chemotherapy . - Life expectancy great equal 6 month . ECOG 0-1 - Should autoimmune disease ; evidence immunocompromised ; serious intercurrent medical illness ; cardiac disease ; prior splenectomy . - No prior treatment MDX-010 ( Ipilimumab ) . - No brain metastasis , history seizure , encephalitis , multiple sclerosis . - No serious hypersensitivity reaction egg product . Design : - This open label , phase I safety trial sequential cohort patient receive fix dose PSA-TRICOM vaccine sargramostim , dose escalation MDX-010 ( Ipilimumab ) . - PROSTVAC -V/TRICOM ( vaccinia ) 2 x 10 ( 8 ) pfu subcutaneously administer initial prim vaccine day 1 cycle 1 . - PROSTVAC -F/TRICOM ( fowlpox ) 1 x 10 ( 9 ) pfu subcutaneously start day 15 follow monthly boosting vaccination . Sargramostim 100 mcg per day administer subcutaneously vaccination site day 1-4 vaccine cycle ( prime boost ) . - MDX-010 ( Ipilimumab ) administer , per assign dose level , 90-minute intravenous infusion day monthly boost vaccination PROSTVAC-F/TRICOM ( fowlpox ) . After 6 course MDX-010 , patient may receive Maintenance dose MDX-010 every 3 month evidence disease progression toxicity , additional 12 month ( equivalent 4 additional MDX-010 course ) . - Monthly boost vaccination PROSTVAC-F/TRICOM ( fowlpox ) sargramostim may continue patient meet study criterion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>INCLUSION CRITERIA : A. Histopathological documentation prostate cancer confirm Laboratory Pathology : NIH Clinical Center , National Institutes Health ( NIH ) , National Naval Medical Center , Walter Reed Army Medical Center prior start study . If pathologic specimen available , patient may enroll pathologist 's report show histologic diagnosis prostate cancer clinical course consistent disease . B . Must metastatic androgen insensitive prostate cancer bone pain require narcotic prior chemotherapy . C. Life expectancy great equal 6 month . D. ECOG performance status 01 . E. No systemic steroid steroid eye drop use within 2 week prior initiation experimental therapy . F. Hematological eligibility parameter Granulocyte count great equal to1,500/mm ( 3 ) Platelet count great equal to100,000/mm ( 3 ) Hgb great equal 9 Gm/dL Lymphocyte count great equal 500/mm ( 3 ) . G. Biochemical eligibility parameter ( within 16 day start therapy ) Hepatic function : Bilirubin le equal 1.5 mg/dl ( OR patient Gilbert 's syndrome , total bilirubin less equal 3.0 mg/dL ) , AST ALT less equal 2.5 time upper limit normal H. No active malignancy within past 12 month ( exception nonmelanoma skin cancer carcinoma situ bladder ) life threaten illness . I . Willing travel NIH followup visit . J . 18 year age great . K. Vaccinianaive vaccinia immune . L. Able understand sign inform consent . M. Agree use adequate contraception prior study entry least 4 month follow last vaccine injection . N. Patients must remain medical castration therapy , unless surgical castration O . Patients must recover acute toxicity relate prior therapy surgery . For chemotherapy typically 34 week . P. Parameters assessment baseline renal function : Serum creatinine institution limit normal , OR creatinine clearance 24 hour urine collection great equal 60 mL/min . Patients must less grade 2 proteinuria ( unless cause determine renal . ) EXCLUSION CRITERIA : A . Patients evidence immunocompromised list . Human immunodeficiency virus positivity due potential decrease tolerance may risk severe side effect . Hepatitis B C positivity Concurrent use topical steroid ( include steroid eye drop ) systemic steroid . Nasal inhale steroid use permit B.Patients autoimmune disease require treatment , Addison 's disease , Hashimoto 's thyroiditis , systemic lupus erythematous , Sjogren syndrome , scleroderma , Goodpasture syndrome , active Grave 's disease . Also exclude patient autoimmune hemolytic anemia , ulcerative hemorrhagic colitis , endocrine disorder ( e.g. , thyroiditis , hyperthyroidism , hypothyroidism , autoimmune hypophysitis/hypopituitarism , adrenal insufficiency ) , sarcoid granuloma , myasthenia gravis , polymyositis , GuillainBarre syndrome . Patients history autoimmunity require systemic immunosuppressive therapy threaten vital organ function include CNS , heart , lung , kidney , skin , GI tract allow . C. History allergy untoward reaction prior vaccination vaccinia virus component vaccinia vaccine regimen . D. Do administer recombinant vaccinia vaccine recipient , least three week vaccination , close household contact ( close household contact share housing close physical contact ) : person active history eczema eczematoid skin disorder ; acute , chronic exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) condition resolve ; pregnant nursing woman ; child 3 year age ; immunodeficient immunosuppressed person ( disease therapy ) , include HIV infection . E. Serious intercurrent medical illness ( e.g. , one require treatment ) would interfere ability patient carry treatment program , include , limited , inflammatory bowel disease , Crohn 's disease , ulcerative colitis , active diverticulitis . F. Patients cardiac disease fatigue , palpitation , dyspnea angina ordinary physical activity ( New York Heart Association class 2 great ) eligible . G. Patients history congestive heart failure objective evidence congestive heart failure physical exam image eligible . H. Patients pulmonary disease fatigue dyspnea ordinary physical activity eligible . I. Concurrent chemotherapy . J . No brain metastasis , history seizure , encephalitis , multiple sclerosis . K. Serious hypersensitivity reaction egg product . L. Prior splenectomy . M. Patients receive prior MDX01 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 7, 2012</verification_date>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Elispot Assay</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic Prostate Cancer</keyword>
</DOC>